89. Lymphangioleiomyomatosis Clinical trials / Disease details
Clinical trials : 39 / Drugs : 46 - (DrugBank : 20) / Drug target genes : 27 - Drug target pathways : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02484664 (ClinicalTrials.gov) | June 15, 2016 | 25/6/2015 | COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC | COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC | Lymphangioleiomyomatosis (LAM) | Drug: Celecoxib | Brigham and Women's Hospital | National Heart, Lung, and Blood Institute (NHLBI) | Completed | 18 Years | 70 Years | Female | 12 | Phase 2 | United States |